Drugs for Myxofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 34)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxorubicin |
Approved, Investigational |
Phase 2, Phase 3 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
2 |
|
Ifosfamide |
Approved |
Phase 2, Phase 3 |
|
3778-73-2 |
3690 |
Synonyms:
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
Asta Z 4942
Holoxan
Ifex
Ifosfamid
Ifosfamida
IFOSFAMIDE
Ifosfamide sterile
Ifosfamidum
Ifosphamide
Ifsofamide
Iphosphamid
|
Iphosphamide
I-phosphamide
Iso endoxan
Iso-endoxan
Isofosfamide
Isophosphamide
Isosfamide
MITOXANA
MJF-9325
NSC-109724
Z-4942
|
|
3 |
|
Daunorubicin |
Approved |
Phase 2, Phase 3 |
|
20830-81-3 |
30323 |
Synonyms:
(+)-Daunomycin
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Cerubidin
Cerubidine
Daunamycin
Daunarubicinum
Dauno rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
DAUNORUBICIN
Daunorubicin Hcl
Daunorubicin hydrochloride
Daunorubicin, Hydrochloride
DAUNORUBICINA
|
DAUNORUBICINE
Daunorubicinum
Daunorubicinum [INN-Latin]
Dauno-rubidomycine
DaunoXome
DM
DM1
FI 6339
FI-6339
Hydrochloride, daunorubicin
Leukaemomycin C
NDC-0082-4155
NSC-83142
Ondena
Rcra Waste No. U059
RP 13057
Rp 13057 Hydrochloride
RP-13057
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
VALRUBICIN IMPURITY, DAUNORUBICIN
|
|
4 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2, Phase 3 |
|
51-75-2 |
4033 |
Synonyms:
2,2'-Dichloro-N-methyldiethylamine
b,Beta'-dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
BIS (2-CHLOROETHYL) METHYLAMINE
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
Caryolysine
Chlorethazine
Chlormethine
Chlormethinum
Cloramin
Clormetina
Embichin
HN2
HN-2
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
MBA
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechloroethamine
Mecloretamina
|
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Mitomen
Mustargen
Mustine
Nitrogen mustard
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
Nitrogranulogen
Nitromin
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC-10107
NSC-128663
NSC-762
Î’,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
5 |
|
Palifosfamide |
Investigational |
Phase 2, Phase 3 |
|
31645-39-3 |
100427 |
Synonyms:
Ifosfamide mustard
Ifosforamide mustard
IPAM
Iphosphoramide mustard
IPM
Isophosphamide mustard
Isophosphoramide mustard
N,N'-BIS-(2-CHLOROETHYL)PHOSPHORIC ACID
|
N,N'-di-(2-chloroethyl)phosphorodiamidic acid
NN'-Bis-(2-chloroethyl)phosphate
NN'-Bis-(2-chloroethyl)phosphoric acid
NSC-297900
Palifosfamide
Palifosfamide-tris
ZIO-201
Zio-201isophosphamide mustard
|
|
6 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3 |
|
|
|
8 |
|
Liposomal doxorubicin |
|
Phase 2, Phase 3 |
|
|
|
9 |
|
Coenzyme M |
Approved, Investigational |
Phase 2 |
|
3375-50-6 |
598 23662354 |
Synonyms:
1-THIOETHANEsulfonate
1-THIOETHANEsulfonIC ACID
1-THIOETHANEsulphonate
1-THIOETHANEsulphonic acid
2 Mercaptoethanesulfonate
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-Mercaptoethanesulphonate
2-Mercaptoethanesulphonate, sodium
2-Mercaptoethanesulphonic acid
2-Mercaptoethylsulfonate
2-Mercaptoethylsulfonic acid
2-Mercaptoethylsulphonate
2-Mercaptoethylsulphonic acid
2-Sulfanylethylsulfonate
2-Sulfanylethylsulfonic acid
2-Sulphanylethylsulphonate
2-Sulphanylethylsulphonic acid
ASTA D 7093
ASTA medica brand OF mesna
ASTAD 7093
ASTA-D 7093
beta-Mercaptoethanesulfonate
beta-Mercaptoethanesulfonic acid
beta-Mercaptoethanesulphonate
beta-Mercaptoethanesulphonic acid
b-Mercaptoethanesulfonate
b-Mercaptoethanesulfonic acid
b-Mercaptoethanesulphonate
b-Mercaptoethanesulphonic acid
Bristol myers squibb brand OF mesna
|
Bristol-myers squibb brand OF mesna
Cell pharm brand OF mesna
Coenzima m
Coenzym m
Coenzyme m
CoM
D-7093
HS-CoM
Kendrick brand OF mesna
Mesna
MESNA cell
Mesna kendrick brand
Mesna sanfer brand
MESNA-cell
Mesnex
Mesnum
Mistabron
Mistabronco
Mitexan
Mucofluid
NSC-113891
Reduced coenzyme m
Reduced com
Sanfer brand OF mesna
Sodium 2-mercaptoethanesulphonate
UCB brand OF mesna
Uromitexan
Ziken
Î’-mercaptoethanesulfonate
Î’-mercaptoethanesulfonic acid
Î’-mercaptoethanesulphonate
Î’-mercaptoethanesulphonic acid
|
|
10 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
11 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
4053 460612 |
Synonyms:
2-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
2-Amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoate
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
AIKERAN
ALANINE NITROGEN MUSTARD
Alkeran
CB-3025
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
L-PAM
L-Phenylalanine mustard
L-PHENYLALANINE MUSTARD (L-PAM)
L-SARCOLYSIN
L-Sarcolysine
L-Sarkolysin
Medphalan
MELFALAN
Melfalano
Melphalan
|
Melphalanum
Mephalan
Merphalan
MLP673
Mustard, phenylalanine
NCI-C04853
NSC-241286
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
Sarcolysin
Sarcolysine
Sarkolysin
SK 15673
SK-15673
|
|
12 |
|
Dactinomycin |
Approved, Investigational |
Phase 2 |
|
50-76-0 |
2019 457193 |
Synonyms:
2-Amino-N,n'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-i)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
Ac-de
ActD
Actinomycin
Actinomycin C1
Actinomycin D
ACTINOMYCIN D 或 DACTINOMYCIN
Actinomycin IV
Cosmegen
Cosmegen lyovac
DACTINOMICINA
Dactinomycin
DACTINOMYCINE
DACTINOMYCINUM
|
GNF-PF-1977
GNF-PF-2290
Lemery brand OF dactinomycin
Lyovac cosmegen
Lyovac, cosmegen
Lyovac-cosmegen
LyovacCosmegen
Meractinomycin
Merck brand OF dactinomycin
Merck frosst brand OF dactinomycin
Merck sharp and dohme brand OF dactinomycin
MSD Brand OF dactinomycin
NCI-C04682
NSC-3053
|
|
13 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
14 |
|
Dexrazoxane |
Approved, Withdrawn |
Phase 2 |
|
24584-09-6 |
71384 |
Synonyms:
(+)-(S)-4,4′-PROPYLENEDI-2,6-PIPERAZINEDIONE
(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione
(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
ADR 529
ADR-529
Cardioxan
Cardioxane
Desrazoxane
Dexrazoxan
Dexrazoxane
Dexrazoxane hydrochloride
Dexrazoxano
Dexrazoxano [INN-Spanish]
Dexrazoxanum
Dexrazoxanum [INN-Latin]
Dextrorazoxane
|
DRX187
Dyzoxane
Eucardion
Hydrochloride, dexrazoxane
ICRF 187
Icrf-187
ICRF187
NSC-169780
Razoxana [INN-Spanish]
Razoxane
Razoxane, (S)-isomer
Razoxane, (S)-isomer, hydrochloride
Razoxanum [INN-Latin]
Razoxin
Tepirone
Troxozone
Zinecard
|
|
15 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
16 |
|
Topotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
123948-87-8, 119413-54-6 |
60699 60700 |
Synonyms:
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(Dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
Hycamptamine
HYCAMPTIN
Hycamtamine
Hycamtin
Hydrochloride, nogitecan
Hydrochloride, topotecan
Nogitecan hydrochloride
NSC-609699
Potactasol
SK And F 104864 a
SK And F104864a
SK And F-104864-a
|
SK&F-S-104864A
SKF-104864
SK-S-104864-A
SmithKline beecham brand OF topotecan hydrochloride
Topotecan
TOPOTECAN HCL
Topotecan hydrochloride
Topotecan lactone
Topotecan monohydrochloride, (S)-isomer
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
|
|
17 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
18 |
|
Antiemetics |
|
Phase 2 |
|
|
|
19 |
|
Anesthetics |
|
Phase 2 |
|
|
|
20 |
|
Emetics |
|
Phase 2 |
|
|
|
21 |
|
Cardiotonic Agents |
|
Phase 2 |
|
|
|
22 |
|
Razoxane |
|
Phase 2 |
|
|
|
Synonyms:
(+,-)-1,2-Bis(3,5-dioxopiperazine-1-yl)propane
Cardioxane
ICI-59118
ICRF 159
ICRF 186
ICRF159
ICRF-159
ICRF186
|
ICRF-186
Razoxana
RAZOXANE
Razoxane mesylate, (R)-isomer
Razoxane, (R)-isomer
Razoxanum
Razoxin
|
|
23 |
|
Protective Agents |
|
Phase 2 |
|
|
|
24 |
|
Alkylating Agents |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
Antineoplastic Agents, Alkylating |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Antirheumatic Agents |
|
Phase 1, Phase 2 |
|
|
|
27 |
|
topoisomerase I inhibitors |
|
Phase 1, Phase 2 |
|
|
|
28 |
|
Avelumab |
Approved, Investigational |
Phase 1 |
|
1537032-82-8 |
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
29 |
|
Nivolumab |
Approved |
Phase 1 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
30 |
|
Immunoglobulins |
|
Phase 1 |
|
|
|
31 |
|
Immune Checkpoint Inhibitors |
|
Phase 1 |
|
|
|
32 |
|
Antibodies |
|
Phase 1 |
|
|
|
33 |
|
Antineoplastic Agents, Immunological |
|
Phase 1 |
|
|
|
34 |
|
Poly I-C |
|
Phase 1 |
|
|
|
Interventional clinical trials:
(show all 14)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) |
Active, not recruiting |
NCT02180867 |
Phase 2, Phase 3 |
Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride |
2 |
Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall |
Unknown status |
NCT03651375 |
Phase 2 |
Sequential chemotherapy - 3 courses of AI |
3 |
Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma |
Completed |
NCT01653028 |
Phase 2 |
Alisertib |
4 |
ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy |
Recruiting |
NCT04480502 |
Phase 2 |
Ipilimumab |
5 |
A Phase II Study of Concurrent Systemic Pembrolizumab and Isolated Limb Infusion (ILI) With Melphalan and Dactinomycin for Patients With Locally Advanced or Metastatic Extremity Sarcoma |
Recruiting |
NCT04332874 |
Phase 2 |
Pembrolizumab;infusion of melphalan and dactinomycin |
6 |
A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma |
Active, not recruiting |
NCT02584309 |
Phase 2 |
Dexrazoxane;Doxorubicin |
7 |
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) |
Enrolling by invitation |
NCT05266196 |
Phase 1, Phase 2 |
Seclidemstat |
8 |
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma |
Terminated |
NCT02601209 |
Phase 1, Phase 2 |
Pazopanib;Pazopanib Hydrochloride;Sapanisertib |
9 |
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas |
Withdrawn |
NCT04906876 |
Phase 2 |
Gemcitabine;Docetaxel;9-ING-41 |
10 |
A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas |
Withdrawn |
NCT05116800 |
Phase 2 |
Gemcitabine;9-ING-41;Docetaxel |
11 |
A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas |
Active, not recruiting |
NCT03009201 |
Phase 1 |
Doxorubicin Hydrochloride;Ribociclib |
12 |
A Phase 1b Dose Escalation and Dose Expansion Study of a CSF1R Inhibitor (DCC-3014) Administered Concurrently With an Anti-PD-L1 Antibody (Avelumab) in Patients With Advanced High-grade Sarcoma |
Active, not recruiting |
NCT04242238 |
Phase 1 |
DCC-3014;Avelumab |
13 |
A Phase I Study of Nivolumab and Intratumoral BO 112 for Resectable Soft Tissue Sarcoma |
Active, not recruiting |
NCT04420975 |
Phase 1 |
|
14 |
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group |
Recruiting |
NCT03967834 |
|
|
|